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equivalent treatments. With only 90 participants, the study has
insufficient power to permit any valid statement on the equiva-
lence of the treatments, a weakness acknowledged by the
authors in the final sentence of their manuscript.2 Equivalency
studies must be designed in accordance with strict methodologic
criteria in order for their conclusions to have any statistical
validity.3 The unambiguous outcome of the Barritt and Jordan
study and the totality of subsequent medical literature and
clinical experience clearly indicate that additional placebo-
controlled clinical trials in the treatment of VTED would be
highly unethical.4 The task at the present is to identify safer and
more effective antithrombotic agents, not to revisit the past.
Michael B. Streiff
Correspondence: Department of Medicine, Johns Hopkins University School of
Medicine, 1025 Ross Building, 720 Rutland Ave, Baltimore, MD 21205
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To the editor:
Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus–infected patients
treated for non-Hodgkin lymphoma
The association of hepatitis viruses with non-Hodgkin lympho-
mas (NHL) is not rare. Several authors have reported an
exceeding prevalence of hepatitis C virus (HCV)1-3 or of
hepatitis B virus (HBV)4,5 infection in patients affected by NHL.
A sustained increase of alanine aminotransferase (ALT) associated
with high levels of HBV viremia (HBV-DNA) 1 to 2 months after
the suspension of chemotherapy has been described in patients
suffering from NHL and infected by HBV.7,8 Recently, a nucleotide
analogue (lamivudine) was shown to be beneficial in HBV-infected
patients with signs of active replication.6 The aim of this study was
to investigate the role of lamivudine to treat or to prevent hepatitis
reactivation in HBV-infected subjects suffering from NHL and
undergoing chemotherapy.
We screened 550 patients (271 males and 279 females) affected
by NHL, ranging in age from 38 to 67 years (median 52 years), and
148 control subjects suffering from metabolic disorders, attending
our institutions during the last 10 years. Of 550 NHL patients, 108
had signs of HBV contact (19%) and 21 were HBsAg-positive
(3.5%), while 86 (15.6%) were HCV-Ab positive with detectable
HCV-RNA in their serum (Table 1). HCV prevalence in NHL was
higher than in the control group (15.6% vs 2.02% P , .000), while
HBsAg-positive prevalence was not significantly different (3.5%
vs 1.3%; ns). No age or sex distribution differences were found in
the various groups (Table 1). NHL patients were treated according
to different therapeutic protocols, which were chosen on the basis
of the specific hystological type and clinical stage of the disease.
Evaluation and follow-up of the patients included medical history,
physical examination, complete blood count, ALT, and markers of
viral hepatitis. Among the 21 HBV-positive NHL patients, 12 had
hepatitis reactivation soon after chemotherapy. Of them, 9 were
treated with lamivudine (Zeffix; Glaxo-Wellcome 100 mg/die), and
3 were not (prelamivudine era). All patients treated recovered from
the viral reactivation and are still followed up, whereas the 3
patients who did not receive lamivudine died of acute liver failure.
In 3 patients lamivudine was given prophylactically during and
after chemotherapy, and the treatment was discontinued 2 months
after the last chemotherapy course. These 3 patients did not show
any sign of acute B hepatitis recurrence (Figure 1). These data
confirm the efficacy of lamivudine, as it has been recently reported
in the literature.9-11 It is noteworthy that, at variance with “sponta-
neous” HBV reactivation in carriers of chronic hepatitis, which
may relapse at lamivudine interruption, the halting of viral
Table 1. Epidemiological characteristics of NHL patients and control subjects
NHL Controls
Total HBV HCV Total HBV HCV
Patients/subjects 550 21 (3.8%) 86 (15.6%) 148 2 (1.3%) 3 (2.02%)
Age (y)
Median 52 45 58 56 51 63
(range) (38-67) (38-64) (42-67) (44-72) (44-58) (49-72)
Sex (m/f) 271/279 11/10 35/51 78/70 2/0 2/1
HBeAg/HBeAb 0/21 0/21 0/1 0/2 0/2 —
HBcAb 108 21 26 13 2 —
HBsAg 21 21 1 2 2 —
HBV-DNA1/HBV-DNA2* — 0/21 0/1 0/2 0/2 —
HBV-DNA1/HBV-DNA2† — 15/0* 1/0 — — —
HCV-Ab/HCV-RNA 86/86 1/1 86/86 3/3 0 3/3
ALT* mean (SD) 35.73 6 21.3 22.27 6 9.4 25.68 6 12.4 33.4 6 15.7 66 6 16.9 62 6 18.5
ALT† mean (SD) 31.67 6 28.5 1051.28 6 898.5‡ 32.8 6 28.7 — — —
*Before chemotherapy.
†1 to 2 months after chemotherapy.
‡Data on 15 patients, 6 patients not collectable.
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replication in NHL HBV–infected subjects persists even after
lamivudine discontinuation. A possible explanation for such a
different behavior is that viral replication in NHL patients is caused
by the immunosuppressive activity of chemotherapy; the replica-
tion is followed by liver attack at postchemotherapy immunologi-
cal recovery, leading to acute or even fulminant hepatitis. The use
of lamivudine, by blocking B virus replication, interrupts the
sequence of events; then, the drug is no more needed when the
recovered immune surveillance re-establishes tolerance to a small
viral load. In our series of NHL patients, while a high percentage of
HBsAg-positive cases (12/21 5 57%) had signs of viral reactiva-
tion, no HCV-infected patient (n 5 86) had ALT increase during or
after chemotherapy. This seems to support the idea that the immune
system might play a different role in the pathogenic mechanism(s)
underlying HCV- and HBV-related chronicity.
In conclusion, our study, while confirming the high prevalence
of HCV infection in NHL patients in specific geographic areas,
points out that HCV reactivation after chemotherapy is not a
clinical problem. By contrast, life expectancy in carriers of
hepatitis B virus may be negatively influenced by the viral
infection. Lamivudine has proven to be a useful drug to prevent or
treat HBV reactivation in patients undergoing chemotherapy for
NHL. This study may represent the basis for a prospective
multicenter trial aimed to assess lamivudine efficacy in avoiding
reactivation of HBV-related hepatitis.
Marcello Persico, Fedele De Marino, Giovanni Di Giacomo Russo,
Alessandro Severino, Bruno Palmentieri, Marco Picardi,
Aristide Morante, Bruno Rotoli, Roberto Torella, and Amalia De Renzo
Correspondence: Marcello Persico, Via T. Tasso, 169, 80127, Naples, Italy.
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To the editor:
Language and the clonal myeloid diseases
Medicine has been fraught with linguistic ambiguities. Some terms are
anachronisms, some lack precision, and some are inconsistent with
current knowledge of the pathobiology of human disease. This terminol-
ogy is disruptive to communication and understanding. Although the
handful of experts in a field may be able to put such diagnostic
designations into perspective, patients, students, physicians, nurses,
demographers, and epidemiologists studying these entities are often
uncertain or confused as to their place in the spectrum of relevant
diseases or in the approaches to their therapy. Such terms should be
amended where possible, but such recategorizations require the imprima-
tur of some organization or group. Although the list is long, 3
noteworthy candidates for change are discussed below.
Refractory anemia. This term has been obsolescent for decades
and should be made obsolete. It derives from an early effort to
distinguish among nonhemolytic anemias by whether they did or
did not respond to iron or specific vitamin-replacement therapy.
Moreover, most of the “refractory anemias” are accompanied by
varying degrees of abnormalities in the concentration or morphol-
ogy of white cells and platelets, leading to fruitless efforts to
subcategorize the varied disease phenotypes. A mutation in a
multipotential hematopoietic cell can produce a nearly limitless
variety of manifestations as the multitude of phenotypes (and
genotypes) of acute myelogenous leukemia indicate. No two are
quite the same in phenotypic features. This variety of form occurs
even within disease subsets with apparent similar cytogenetic
abnormalities. The move toward genetic classification will be
useful to motivate molecularly targeted therapists, but the best
classification of leukemia for the patient will be by the curative
drug to which it responds (ie, cladrabine-curable leukemia). Today,
the anemias, bicytopenias, and multicytopenias in the array of
refractory anemias are known to be neoplasms, that is, the clonal
expression of a mutant multipotential hematopoietic cell. Thus, the
Figure 1. Lamivudine nontreated, treated, and pretreated NHL patients. ALT
values of HBV-infected NHL patients nontreated () (n 5 3), treated with lamivudine
after chemotherapy (E) (n 5 9), and pretreated with lamivudine (during and after
chemotherapy) (f) (n 5 3).
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